PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

• Cecilia Carmen Carpio Segura,
• Manjusha Namuduri,
• Dishan Liu,
• Nickolas A. Sophos,
• Min Zhu,
• Ayesha Sabir,
• Jurriaan Brouwer-Visser,
• Aafia Chaudhry,
• Hesham Mohamed,
• Alejandro Martin Garcia-Sancho

Affiliations

Cecilia Carmen Carpio Segura

1 Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Department of Hematology, Experimental Hematology, Barcelona, Spain

Manjusha Namuduri

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Dishan Liu

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Nickolas A. Sophos

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Min Zhu

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Ayesha Sabir

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Jurriaan Brouwer-Visser

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Aafia Chaudhry

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Hesham Mohamed

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Alejandro Martin Garcia-Sancho

3 Hospital Universitario de Salamanca, IBSAL, Department of Hematology, Salamanca, Spain